Boston Life Sciences Announces Allowance of Inosine Therapy Patent.Business Editors and Health/Medical Writers BOSTON--(BW HealthWire)--May 17, 2002 Claims for the therapeutic use of Inosine inosine /in·o·sine/ (I) (in´o-sen) a purine nucleoside containing the base hypoxanthine and the sugar ribose, which occurs in transfer RNAs and as an intermediate in the degradation of purines and purine nucleosides to uric acid and in to treat stroke and other CNS See Continuous net settlement. CNS See continuous net settlement (CNS). injuries granted by Patent and Trademark Office (PTO PTO abbr. 1. Parent Teacher Organization 2. or p.t.o. please turn over 3. power takeoff PTO or pto please turn over Noun 1. ) Boston Life Sciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BLSI BLSI Boston Life Sciences, Inc. ) announced that the Company has received written Notice of Allowance of claims contained in the Company's licensed Inosine patent application. The allowed claims cover the use of Inosine to treat stroke and spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. in a human subject as well as the method of administration. The patent is expected to issue within the next few months, the Company said. Inosine is a naturally-occurring small molecule that was discovered by the Company's collaborating scientists to have extraordinary axon growth-promoting activity in nerve cells of the Central Nervous System (CNS). Specifically, Inosine activates a newly-discovered enzyme (as elucidated by the BLSI team) that specifically controls axon growth in these nerve cells. Rats subjected to severe experimental strokes demonstrated significant recovery when treated with Inosine for 6 weeks. The functional recovery in Inosine-treated rats was shown to correlate with the growth of new, compensatory axons in their brains. The results of these studies have been accepted for publication in a premier peer-reviewed journal. "The allowance of these important patent claims further strengthens our proprietary position in the field of nerve regeneration, as we move towards initial human testing of this potentially revolutionary treatment for stroke," stated Dr. Marc Lanser, Chief Scientific Officer of BLSI. "The published results with Inosine have been and continue to be without precedence in the field of axon regeneration. We believe that Inosine will be the first truly regenerative potential therapy for stroke to enter human clinical trials. We are looking forward to working with the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. to secure approval for the initiation of one or more Phase I clinical trials and the publication of the above-mentioned landmark pre-clinical study in the near future," added Dr. Lanser. BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder attention deficit hyperactivity disorder (ADHD), formerly called hyperkinesis or minimal brain dysfunction, a chronic, neurologically based syndrome characterized by any or all of three types of behavior: hyperactivity, distractibility, and impulsivity. (ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or ) as well as treatments for cancer, autoimmune disease, and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . BLSI's products in development include: ALTROPANE(TM) and FLUORATEC(TM) radioimaging agents for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion